Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
1997-8-14
|
pubmed:abstractText |
The clinical course of renal cell carcinoma (RCC) is highly variable. Overexpression of the p53 protein has been suggested as a possible prognostic parameter in RCC. Overexpression of the mdm-2 oncogene product has been shown to interact with the p53 function. To investigate the immunohistochemical overexpression of mdm-2 protein in comparison with that of p53 protein in RCC, 50 nonpapillary pT3 RCCs were immunostained for p53 protein (DO-7) and mdm-2 (IF2). Tumor growth fraction (Ki-67 labeling index; MIB-1) was determined by immunohistochemistry. p53 positivity was detected in 16% of tumors. mdm-2 overexpression was seen in 30% of RCCs. There was a significant association between p53 and mdm-2 immunostaining (P = 0.0006), suggesting that mdm-2 protein may contribute to p53 protein stabilization in RCC. p53 overexpression was associated with a high Ki-67 LI (P = 0.0002), suggesting that p53 overexpression is involved in growth control in RCC. Survival analysis showed that Ki-67 LI (P = 0.04) and p53 overexpression were associated with poor prognosis (P = 0.0021), whereas mdm-2 overexpression was not related to patient outcome (P = 0.73). A Cox regression analysis revealed tumor stage (P < 0.001) and p53 overexpression (P < 0.05) to be independent prognostic parameters. It is concluded that p53 but not mdm-2 may be of practical relevance in predicting patient prognosis in RCC.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Ki-67 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/MDM2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Nuclear Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-mdm2,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0300-5623
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
25 Suppl 1
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
S25-30
|
pubmed:dateRevised |
2005-11-17
|
pubmed:meshHeading |
pubmed-meshheading:9079753-Carcinoma, Renal Cell,
pubmed-meshheading:9079753-Cell Division,
pubmed-meshheading:9079753-Humans,
pubmed-meshheading:9079753-Immunohistochemistry,
pubmed-meshheading:9079753-Ki-67 Antigen,
pubmed-meshheading:9079753-Kidney,
pubmed-meshheading:9079753-Kidney Neoplasms,
pubmed-meshheading:9079753-Neoplasm Proteins,
pubmed-meshheading:9079753-Nuclear Proteins,
pubmed-meshheading:9079753-Prognosis,
pubmed-meshheading:9079753-Proto-Oncogene Proteins,
pubmed-meshheading:9079753-Proto-Oncogene Proteins c-mdm2,
pubmed-meshheading:9079753-Regression Analysis,
pubmed-meshheading:9079753-Tumor Suppressor Protein p53
|
pubmed:year |
1997
|
pubmed:articleTitle |
p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma.
|
pubmed:affiliation |
Institute of Pathology, University of Basel, Switzerland.
|
pubmed:publicationType |
Journal Article
|